Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease

Neurology

Volumn 81, Issue 21, 2013, Pages 1819-1826

  Davis, Ryan L ^a   Liang, Christina ^a,b   Edema Hildebrand, Fabienne ^b   Riley, Catherine ^b   Needham, Merrilee ^b   Sue, Carolyn M ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

AUC area under the curve; BMI body mass index; CI confidence interval; FGF 21 fibroblast growth factor 21; IQR interquartile range; MRC Medical Research Council; OR odds ratio; RNSH Royal North Shore Hospital; ROC receiver operating characteristics

Indexed keywords

BIOLOGICAL MARKER; CREATINE KINASE; FIBROBLAST GROWTH FACTOR 21; LACTIC ACID; PYRUVIC ACID;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FEMALE; HUMAN; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MIDDLE AGED; NEUROMUSCULAR DISEASE; NONMITOCHONDRIAL NEUROMUSCULAR DISEASE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TERTIARY CARE CENTER; VALIDITY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIAL DISEASES; MUSCULAR DISEASES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84891909814     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000436068.43384.ef     Document Type: Article

References (25)

1. Manwaring N, Jones MM, Wang JJ, et al. Population prevalence of the MELAS A3243G mutation. Mitochondrion 2007;7:230-233.
2. Manwaring N, Wang JJ, Mitchell P, Sue CM. Mitochondrial DNA disease prevalence: still underrecognized? Ann Neurol 2008;64:471.
3. Elliott HR, Samuels DC, Eden JA, Relton CL, Chinnery PF. Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet 2008;83:254-260.
4. Vandebona H,Mitchell P,Manwaring N, et al. Prevalence of mitochondrial 1555A/G mutation in adults of European descent. N Engl J Med 2009;360:642-644.
5. Sue CM. Mitochondrial disease: recognising more than just the tip of the iceberg. Med J Aust 2010;193:195-196.
6. Davis RL, Sue CM. The genetics of mitochondrial disease. Semin Neurol 2011;31:519-530.
7. Haas RH, Parikh S, Falk MJ, et al. The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab 2008;94:16-37.
8. Suomalainen A. Biomarkers for mitochondrial respiratory chain disorders. J Inherit Metab Dis 2011;34:277-282.
9. Oglesbee D, Freedenberg D, Kramer KA, Anderson BD, Hahn SH. Normal muscle respiratory chain enzymes can complicate mitochondrial disease diagnosis. Pediatr Neurol 2006;35:289-292.
10. Debray FG, Mitchell GA, Allard P, et al. Diagnostic accuracy of blood lactate-to-pyruvate molar ratio in the differential diagnosis of congenital lactic acidosis. Clin Chem 2007;53:916-921.
11. Suomalainen A, Elo JM, Pietilainen KH, et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol 2011;10:806-818.
12. Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008;149:6018-6027.
13. Chau MD, Gao J, Yang Q, Wu Z, Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci USA 2010;107:12553-12558.
14. Woo YC, Xu A, Wang Y, Lam KS. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol 2013;78:489-496.
15. Walker UA, Collins S, Byrne E. Respiratory chain encephalomyopathies: a diagnostic classification. Eur Neurol 1996;36:260-267.
16. Medical Research Council of the United Kingdom. Aids to Examination of the Peripheral Nervous System. Palo Alto: CA Pendragon House; 1978.
17. Singh G. Determination of Cutoff score for a diagnostic test. Internet J Lab Med 2007;2.
18. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003;56:1129-1135.
19. Galman C, Lundasen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008;8:169-174.
20. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008;57:1246-1253.
21. Cuevas-Ramos D, Almeda-Valdes P, Gomez-Perez FJ, et al. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels. Eur J Endocrinol 2010;163:469-477.
22. Dostalova I, Kavalkova P, Haluzikova D, et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008;93:3627-3632.
23. Fazeli PK, Misra M, Goldstein M, Miller KK, Klibanski A. Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. J Clin Endocrinol Metab 2010;95:369-374.
24. Kim KH, Jeong YT, Oh H, et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med 2013;19: 83-92.
25. Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators: a critical appraisal. Cell Metab 2012;16:693-705.